{"id":1523,"date":"2016-07-08T16:21:05","date_gmt":"2016-07-08T23:21:05","guid":{"rendered":"http:\/\/www.oliveviewim.org\/blog\/?p=1523"},"modified":"2016-07-08T16:21:05","modified_gmt":"2016-07-08T23:21:05","slug":"atrial-fibrillation","status":"publish","type":"post","link":"https:\/\/www.uclaoliveview.org\/medicine\/blog\/?p=1523","title":{"rendered":"Atrial Fibrillation"},"content":{"rendered":"<p><em>Thank you Dr. Feng\u00a0for an excellent presentation on the management of atrial\u00a0fibrillation\u00a0in the setting of acute de-compensated heart failure<\/em><\/p>\n<p><strong>Teaching Points<\/strong><\/p>\n<ul>\n<li>Important components of management: hemodynamic stability, rate control, anti-coagulation<\/li>\n<li>Rate control agents: beta blockers, calcium channel blockers (not preferred in HF), digoxin and amiodarone (also an anti-arrhythmic)<\/li>\n<li>Antiarrhythmics for afib are Class IC or III\n<ul>\n<li>IC: flecainide, propafeonone<\/li>\n<li>III: amiodarone, dronedarone, sotalol, dofetilide<\/li>\n<\/ul>\n<\/li>\n<li>Anti-coagulation: indicated if CHADSVASc \u2265 2 (warfarin or newer agents, ie apixaban or rivaroxaban)<\/li>\n<\/ul>\n<p><!--more--><\/p>\n<p><b>PowerPoint<\/b><strong>:<\/strong><br \/>\n<a href=\"http:\/\/www.oliveviewim.org\/blog\/wp-content\/uploads\/2016\/07\/Morning-Report-07-08-2016.pptx\">Morning Report &#8211; 07-08-2016<\/a><\/p>\n<p><strong>Further Reading:<\/strong><br \/>\n<a href=\"http:\/\/www.oliveviewim.org\/blog\/wp-content\/uploads\/2016\/07\/AFFIRM-Trial.pdf\">A comparison of rate control and rhythm control in patients with atrial fibrillation (AFFIRM trial)<br \/>\n<\/a><a href=\"http:\/\/www.oliveviewim.org\/blog\/wp-content\/uploads\/2016\/07\/RACE-II-Trial.pdf\">Lenient versus strict rate control in patients with atrial fibrillation (RACE II trial)<\/a><a href=\"http:\/\/www.oliveviewim.org\/blog\/wp-content\/uploads\/2016\/07\/AFFIRM-Trial.pdf\"><br \/>\n<\/a><a href=\"http:\/\/www.oliveviewim.org\/blog\/wp-content\/uploads\/2016\/07\/RE-LY-Trial.pdf\">Dabigatran versus warfarin in patients with atrial fibrillation (RE-LY trial)<\/a><a href=\"http:\/\/www.oliveviewim.org\/blog\/wp-content\/uploads\/2016\/07\/AFFIRM-Trial.pdf\"><br \/>\n<\/a><a href=\"http:\/\/www.oliveviewim.org\/blog\/wp-content\/uploads\/2016\/07\/ROCKET-AF-Trial.pdf\">Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (ROCKET-AF trial)<br \/>\n<\/a><a href=\"http:\/\/www.oliveviewim.org\/blog\/wp-content\/uploads\/2016\/07\/ARISTOTLE-Tiral.pdf\">Apixaban versus Warfarin in Patients with Atrial Fibrillation (ARISTOTLE trial<\/a>)<a href=\"http:\/\/www.oliveviewim.org\/blog\/wp-content\/uploads\/2016\/07\/AFFIRM-Trial.pdf\"><br \/>\n<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Thank you Dr. Feng\u00a0for an excellent presentation on the management of atrial\u00a0fibrillation\u00a0in the setting of acute de-compensated heart failure Teaching Points Important components of management: hemodynamic stability, rate control, anti-coagulation Rate control agents: beta blockers, calcium channel blockers (not preferred in HF), digoxin and amiodarone (also an anti-arrhythmic) Antiarrhythmics for afib are Class IC or [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":1550,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,1],"tags":[],"class_list":["post-1523","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-inpatient-report","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/www.uclaoliveview.org\/medicine\/blog\/index.php?rest_route=\/wp\/v2\/posts\/1523","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.uclaoliveview.org\/medicine\/blog\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.uclaoliveview.org\/medicine\/blog\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.uclaoliveview.org\/medicine\/blog\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.uclaoliveview.org\/medicine\/blog\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1523"}],"version-history":[{"count":0,"href":"https:\/\/www.uclaoliveview.org\/medicine\/blog\/index.php?rest_route=\/wp\/v2\/posts\/1523\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.uclaoliveview.org\/medicine\/blog\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1523"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.uclaoliveview.org\/medicine\/blog\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1523"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.uclaoliveview.org\/medicine\/blog\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1523"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}